June 1 2018, 12-17:00pm, Queen Mary University of London: William Harvey Research Institute

Join our Lunch and Learn Seminar, hosted with Dr. Ahuva Nissim, Queen Mary University of London, to explore the latest research and developments in autoimmune disease, with cutting edge research on disorders such as ALS and MS presented by renowned academic speakers.

June 12, 10am ET

Join our webinar supporting the 1st International NASH Day, to explore a new highly translational mouse model for NAFLD/NASH with concurrent metabolic dysregulation. Dr Judith Gorkski will present characterization and case study data showing how the FATZO mouse can accelerate the preclinical discovery of new NASH treatments. All webinar attendees will receive a free T-shirt to show your support for NASH awareness.

June 20, 2018 - Janssen Research Campus, Beerse, Belgium

Join our inflammation and immuno-oncology symposium, jointly organized with Janssen Pharmaceutica and hosted at their research campus in Beerse, Belgium, to explore the latest developments in inflammatory and I/O molecular mechanisms, preclinical disease models, and the current research on novel therapeutic applications.

Enhance your early stage oncology and immuno-oncology drug development through expanded PDX model use. Learn more about humanized PDX for I/O studies, and explore PDX-derived cell lines and 3D PDX screening panels for in vitro/ex vivo assays, for a fully integrated preclinical research continuum.

May 23, 10am ET / May 24, 2pm ET

Presented by Dr Toni Jun, this webinar explores immunocompetent murine immuno-oncology models, with a direct comparison between syngeneics and murine tumor homografts. Learn how to choose between these model types for immuno-oncology applications, exploit model specific features and minimize limitations, as well as how to use these models to help predict patient response to immunotherapy.

Download our 13 scientific posters covering a wide variety of preclinical oncology and immuno-oncology platforms including NGS and transcriptomic PDX analysis, novel murine homograft models, as well as PBMC and humanized drug target models for immunotherapy assessment.

Fast track your preclinical oncology research with our off-the-shelf reagents, including in vivo grade antibodies and isotype controls, recombinant cell lines, biochemicals, reference standards, TMAs, kits, and more!

Presented by Dr. Joseph Maxwell of Finch Therapeutics, this webinar explores how to identify key inflammatory diseases for microbiome therapies and tailor drug development towards selected or whole community microbiota using a human-first platform. Learn more about the microbiota's role in IBD, Crohn's, and other diseases, how specific microbes drive clinical phenotypes, and novel approaches to customizing microbiome drug development.

Presented by Dr John MacDougall, this webinar introduces the integrated use of patient-derived xenograft (PDX) models across preclinical research for more translational studies. Learn more on the importance of using highly translational preclinical cancer models, leveraging the benefits and limitations of in vitro, ex vivo, and in vivo PDX study types, and how this variety of platforms can be used for immuno-oncology studies.

Presented by Dr Toni Jun, this webinar introduces a one stop, integrated in vitro/ex vivo I/O assay plaform designed to effciently progress immunotherapy drug development. Learn how to monitor and assess TIL populations and functions, explore the microbiome's role in immunotherapy, and understand a wide range of functional characteristics across the I/O field including tumor microenvironment regulation.

Presented by Dr Henry Li, this webinar explores the detailed data analysis behind the industry's first large-scale, staggered, syngeneic screening platform for immunotherapy development. Learn how this platform can improve efficiency and reproducibility while reducing cost, how comprehensive immunophenotyping and profiling data is used to address key study design questions, and how RNAseq and FACS/IHC analysis are used for biomarker discovery.

Enhance your humanized mouse immuno-oncology studies through a deeper understanding of model immunological features and optimized uses. Learn more about immune system humanization strategies, and how these result in different models with contrasting features and limitations, then explore model applications through cancer pharmacology case studies.

Learn more about the world's largest patient-derived xenograft (PDX) collection. Download or request a poster today.

Hear Dr Henry Li, Vice President of Biomarker and Diagnostic Technology present our AACR-NCI-EORTC 2017 selected Short Talk titled 'Transcriptomic analysis of patient-derived xenografts reveals heterogeneity in human and mouse stroma/immune compartments'

Learn how to leverage CrownBio's integrated Oncology Portfolio to advance your Target Identification studies. Watch our webinar presented by Michelle Mack.

Transform your preclinical oncology drug development, with mouse clinical trials using patient-derived xenograft (PDX) models. Learn how the different types of MCT are executed, which is the best fit for your specific drug discovery program, and how they provide the perfect framework for biomarker discovery.

Presented by Dr. Keefe Chng and Dr Judith Gorski this webinar will help guide you through a study design process that will enable the greatest opportunity to generate robust, high-quality data, that gives maximum confidence to select new drug candidates and regulatory submissions.

This White Paper explores a unique platform of highly translational models recapitulating multiple aspects of disease progression as seen in humans, for preclinical efficacy studies.

Our Translational Platforms enable our clients to identify the right patients for the right treatment. Having models which more accurately mimic human disease and population dynamics are key to successfully translating promising compounds into successful clinical candidates, whether treating Oncology or Diabetes related diseases.

Our scientific acumen and experience will give you a deeper understanding of not just the pharmacological profile of your compound, but more importantly, a clear understanding of which compounds to progress into the clinic. Take a look at our publications to get a deeper understanding of the depth of our scientific expertise.

We help our clients solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease by answering some of the most challenging questions about human biology.